Tango Therapeutics, Inc.
6 clinical trials · Sponsor
◉ Watch Tango Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (NCT06922591) | Tango Therapeutics, Inc. | 2025-05-31 |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss (NCT06810544) | Tango Therapeutics, Inc. | 2025-03-24 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors (NCT06065059) | Tango Therapeutics, Inc. | 2023-12-08 |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (NCT05887492) | Tango Therapeutics, Inc. | 2023-06-12 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors (NCT05732831) | Tango Therapeutics, Inc. | 2023-05-26 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors (NCT05275478) | Tango Therapeutics, Inc. | 2022-03-23 |
Track Tango Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.